DK2177536T3 - Antistoffer mod amyloid-beta-peptid - Google Patents

Antistoffer mod amyloid-beta-peptid

Info

Publication number: DK2177536T3
Authority: DK; Denmark
Prior art keywords: antibodies; amyloid beta; beta peptide; peptide; amyloid
Prior art date: 2006-03-30

Application number

DK09178407.4T

Other languages

English (en)

Inventor

Stephen Anthony Burbidge

Jonathan Henry Ellis

Susannah K Ford

Volker Germaschewski

Umesh Kumar

Karen Louise Philpott

Peter Ernest Soden

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-30

Filing date

2007-03-27

Publication date

2014-07-14

2007-03-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2014-07-14 Application granted granted Critical

2014-07-14 Publication of DK2177536T3 publication Critical patent/DK2177536T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK09178407.4T 2006-03-30 2007-03-27 Antistoffer mod amyloid-beta-peptid DK2177536T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78758806P	2006-03-30	2006-03-30
EP07727401A EP1996621B1 (en)	2006-03-30	2007-03-27	Antibodies against amyloid-beta peptide

Publications (1)

Publication Number	Publication Date
DK2177536T3 true DK2177536T3 (da)	2014-07-14

Family

ID=38284050

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK09178407.4T DK2177536T3 (da)	2006-03-30	2007-03-27	Antistoffer mod amyloid-beta-peptid
DK07727401.7T DK1996621T3 (da)	2006-03-30	2007-03-27	Antistoffer mod beta-amyloid-peptid

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK07727401.7T DK1996621T3 (da)	2006-03-30	2007-03-27	Antistoffer mod beta-amyloid-peptid

Country Status (32)

Country	Link
US (3)	US8227576B2 (da)
EP (2)	EP2177536B1 (da)
JP (1)	JP5103466B2 (da)
KR (2)	KR101263294B1 (da)
CN (2)	CN103539857A (da)
AR (1)	AR060332A1 (da)
AT (1)	ATE451392T1 (da)
AU (1)	AU2007233831B2 (da)
BR (1)	BRPI0709246A2 (da)
CA (1)	CA2647808C (da)
CR (1)	CR10347A (da)
CY (1)	CY1109877T1 (da)
DE (1)	DE602007003703D1 (da)
DK (2)	DK2177536T3 (da)
EA (1)	EA015654B9 (da)
ES (2)	ES2338179T3 (da)
HR (2)	HRP20100115T1 (da)
IL (1)	IL193695A (da)
JO (1)	JO2576B1 (da)
MA (1)	MA30337B1 (da)
MX (1)	MX2008012483A (da)
MY (1)	MY149630A (da)
NO (1)	NO20083793L (da)
NZ (1)	NZ571038A (da)
PE (1)	PE20080181A1 (da)
PL (2)	PL1996621T3 (da)
PT (2)	PT1996621E (da)
SI (2)	SI2177536T1 (da)
TW (1)	TWI385179B (da)
UA (1)	UA94734C2 (da)
WO (1)	WO2007113172A2 (da)
ZA (1)	ZA200807911B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
EP1583562B1 (en)	2003-01-06	2011-06-15	Angiochem Inc.	Angiopep-1, related compounds, and uses thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8916165B2 (en)	2004-12-15	2014-12-23	Janssen Alzheimer Immunotherapy	Humanized Aβ antibodies for use in improving cognition
CA2589860A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
AU2006319358B2 (en)	2005-11-30	2012-01-19	AbbVie Deutschland GmbH & Co. KG	Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko)	2005-11-30	2014-07-08	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
PL2046833T3 (pl)	2006-07-14	2014-01-31	Ac Immune Sa	Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
US7931899B2 (en)	2007-05-14	2011-04-26	Medtronic, Inc	Humanized anti-amyloid beta antibodies
US8323654B2 (en)	2007-05-14	2012-12-04	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
DK2182983T3 (da) *	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
WO2009024567A1 (en) *	2007-08-20	2009-02-26	Glaxo Group Limited	Production method
GB0718737D0 (en) *	2007-09-25	2007-11-07	Glaxo Group Ltd	Antibodies
AU2008311367B2 (en)	2007-10-05	2014-11-13	Ac Immune S.A.	Use of anti-amyloid beta antibody in ocular diseases
RU2538709C2 (ru) *	2007-10-05	2015-01-10	Дженентек, Инк.	Гуманизированное антитело
PL2592148T3 (pl) *	2007-10-12	2019-01-31	F. Hoffmann-La Roche Ag	Ekspresja białka z wielu kwasów nukleinowych
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2586797A3 (en) *	2007-11-27	2013-07-24	Medtronic, Inc.	Humanized anti-amyloid beta antibodies
AU2008334637B2 (en) *	2007-12-11	2014-08-07	Glaxo Group Limited	Antigen binding proteins
EP2261254A3 (en) *	2007-12-21	2011-04-13	Amgen, Inc	Anti-amyloid antibodies and uses thereof
AR071634A1 (es)	2008-05-06	2010-06-30	Glaxo Group Ltd	Nanoparticulas para encapsulacion de agentes biologicamente activos
MX2011004017A (es)	2008-10-15	2011-06-24	Angiochem Inc	Conjugados de agonistas glp-1 y usos de los mismos.
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
AU2009322043A1 (en)	2008-12-05	2011-07-07	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI1015295A2 (pt)	2009-04-20	2016-05-31	Angiochem Inc	traamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2.
CA2766537A1 (en)	2009-07-02	2011-01-06	Angiochem Inc.	Multimeric peptide conjugates and uses thereof
NZ598685A (en)	2009-09-11	2013-05-31	Probiodrug Ag	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2308897A1 (en) *	2009-10-09	2011-04-13	Pierre Fabre Medicament	Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
MX2012009460A (es)	2010-03-03	2012-09-12	Boehringer Ingelheim Int	Polipeptidos biparatopicos de union abeta.
CA2796339C (en)	2010-04-15	2020-03-31	Abbott Laboratories	Amyloid-beta binding proteins
WO2011149461A1 (en) *	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
CA2806909C (en)	2010-07-30	2019-12-17	Ac Immune S.A.	Safe and functional humanized antibodies
JP6147665B2 (ja)	2010-08-14	2017-06-14	アッヴィ・インコーポレイテッド	アミロイドベータ結合タンパク質
WO2012075037A1 (en)	2010-11-30	2012-06-07	Genentech, Inc.	Low affinity blood brain barrier receptor antibodies and uses therefor
EP2670434B1 (en)	2011-01-31	2018-12-26	Tau Bio-Logic Corp.	Treatment of tauopathies
WO2012145714A2 (en)	2011-04-22	2012-10-26	Emergent Product Development Seattle, Llc	Prostate-specific membrane antigen binding proteins and related compositions and methods
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
MY181743A (en)	2012-05-21	2021-01-06	Genentech Inc	Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) *	2012-10-25	2014-03-10	Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук	Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
JP2016529482A (ja)	2013-06-19	2016-09-23	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	新規アッセイ
CN104558172A (zh) *	2015-01-04	2015-04-29	东南大学	一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
WO2016205367A1 (en)	2015-06-15	2016-12-22	Angiochem Inc.	Methods for the treatment of leptomeningeal carcinomatosis
CN108367004B (zh)	2015-09-21	2022-09-13	阿帕特夫研究和发展有限公司	Cd3结合多肽
WO2017072090A1 (en) *	2015-10-27	2017-05-04	Glaxosmithkline Intellectual Property Development Limited	Combination therapy
US11530257B2 (en) *	2017-06-29	2022-12-20	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en)	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
EP3819311A4 (en) *	2018-07-17	2022-08-17	Jiangsu Hengrui Medicine Co., Ltd.	ANTI-ABETA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
US11155609B2 (en)	2019-04-05	2021-10-26	TauC3 Biologies Limited	Anti-TAUC3 antibodies and uses thereof
CN116348487A (zh)	2020-07-23	2023-06-27	欧萨尔普罗席纳有限公司	抗淀粉样β抗体
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
CN114591917B (zh) *	2022-05-07	2022-09-02	北京第一生物化学药业有限公司	产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
CN114591918B (zh) *	2022-05-07	2022-07-26	北京第一生物化学药业有限公司	产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) *	2022-09-08	2023-05-11	주식회사 알츠코리아	아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) *	2024-08-19	2024-11-22	成都迈科康生物科技有限公司	一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5880268A (en) *	1992-01-27	1999-03-09	Icos Corporation	Modulators of the interaction between ICAM-R and αd /CD18
DK0994728T3 (da) *	1997-04-09	2008-12-01	Intellect Neurosciences Inc	Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US7179892B2 (en) *	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
WO2000031548A1 (en) *	1998-11-25	2000-06-02	Scios Inc.	Prevention and treatment of amyloid-associated disorders
DZ3295A1 (fr) *	2000-02-24	2001-08-30		Anticorps humanises sequestrant un peptide amyloide .beta.
CA2426030C (en) *	2000-11-03	2013-12-31	The J. David Gladstone Institutes	Methods of treating disorders related to apoe
WO2004029629A1 (en) *	2002-09-27	2004-04-08	Janssen Pharmaceutica N.V.	N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) *	2002-10-08	2004-04-09	Pro Cord Spa	Schienale di sedia.
MXPA05003621A (es) *	2002-10-09	2005-10-19	Rinat Neuroscience Corp	Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.

2007
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en not_active Ceased
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 HR HR20100115T patent/HRP20100115T1/hr unknown
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/en not_active Not-in-force
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active Expired - Fee Related
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Withdrawn
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 EP EP07727401A patent/EP1996621B1/en not_active Not-in-force
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140050719A1 (en)	2014-02-20
PL1996621T3 (pl)	2010-05-31
CY1109877T1 (el)	2014-09-10
US20160024197A1 (en)	2016-01-28
SI2177536T1 (sl)	2014-09-30
NZ571038A (en)	2011-03-31
PT1996621E (pt)	2010-03-08
ES2338179T3 (es)	2010-05-04
CN103539857A (zh)	2014-01-29
CN101415729B (zh)	2013-09-04
IL193695A (en)	2012-05-31
NO20083793L (no)	2008-10-13
TWI385179B (zh)	2013-02-11
BRPI0709246A2 (pt)	2011-07-12
CN101415729A (zh)	2009-04-22
EP1996621B1 (en)	2009-12-09
US8227576B2 (en)	2012-07-24
HRP20100115T1 (hr)	2010-04-30
EA015654B9 (ru)	2012-01-30
KR20120093400A (ko)	2012-08-22
WO2007113172A2 (en)	2007-10-11
JO2576B1 (en)	2011-02-27
AU2007233831B2 (en)	2013-02-14
KR101263294B1 (ko)	2013-06-04
PE20080181A1 (es)	2008-03-16
ZA200807911B (en)	2009-11-25
HK1122311A1 (en)	2009-05-15
IL193695A0 (en)	2011-08-01
JP2009531380A (ja)	2009-09-03
JP5103466B2 (ja)	2012-12-19
CA2647808C (en)	2015-11-17
EP2177536A1 (en)	2010-04-21
EA200801842A1 (ru)	2009-02-27
ES2484967T3 (es)	2014-08-12
US9193784B2 (en)	2015-11-24
PT2177536E (pt)	2014-08-22
CR10347A (es)	2008-10-29
KR20080113273A (ko)	2008-12-29
HK1138015A1 (en)	2010-08-13
ATE451392T1 (de)	2009-12-15
WO2007113172A3 (en)	2007-11-29
DK1996621T3 (da)	2010-04-19
SI1996621T1 (sl)	2010-04-30
HRP20140618T1 (hr)	2014-08-15
EP2177536B1 (en)	2014-06-04
CA2647808A1 (en)	2007-10-11
PL2177536T3 (pl)	2014-11-28
AU2007233831A1 (en)	2007-10-11
TW200815466A (en)	2008-04-01
MA30337B1 (fr)	2009-04-01
EA015654B1 (ru)	2011-10-31
DE602007003703D1 (de)	2010-01-21
MY149630A (en)	2013-09-13
US20110142824A1 (en)	2011-06-16
EP1996621A2 (en)	2008-12-03
MX2008012483A (es)	2008-10-10
UA94734C2 (ru)	2011-06-10
AR060332A1 (es)	2008-06-11

Publication	Publication Date	Title
DK2177536T3 (da)	2014-07-14	Antistoffer mod amyloid-beta-peptid
CY2021027I2 (el)	2021-12-31	Σκευασματα αντισωματων anti-cd20
IL269201A (en)	2019-11-28	Glycosylated antibodies
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
DK2046826T3 (da)	2011-10-24	Exendin-fusionsproteiner
DK3118221T3 (da)	2019-09-23	Proteiner
EP2215246A4 (en)	2011-08-10	PROTEIN SCAFFOLDS
CY2016029I2 (el)	2017-04-26	Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
CR10556A (es)	2009-04-03	Humanized antibody against amyloid beta
SI2126093T1 (sl)	2013-01-31	IzboljĹˇanje priprave proteinov
DK1976877T3 (da)	2014-03-31	Monoklonale antistoffer mod amyloid-beta-protein og anvendelser heraf
DE602007013151D1 (de)	2011-04-28	Pufferelement
EP2337801A4 (en)	2012-07-25	MUC1 * antibody
BRPI0819210A2 (pt)	2015-06-23	Anticorpos de proteína g anti-rsv
BRPI0914889A2 (pt)	2015-11-24	peptídeo glp-1 adicionado de cadeia oligossacarídica
BRPI0814587A2 (pt)	2015-01-20	Peptídeos antibióticos
BRPI0814971A2 (pt)	2015-02-03	Proteína
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DK2330131T3 (da)	2015-01-05	Antistoffer mod HER2-trunkeret variant CTF-611
EP2348042A4 (en)	2012-03-28	MODIFIED AMYLOID BETA PEPTIDE
FI20070937A0 (fi)	2007-12-04	Perhekeinu
EP2131031A4 (en)	2013-01-02	ENGINE
EP2101804A4 (en)	2010-06-16	PROANGIOGENIC PEPTIDES
FR2909092B1 (fr)	2012-10-19	Nouveaux anticorps anti-proliferation